Generic and biosimilar sector welcomes the Government's 'cost of living' Budget

"The affordable medicines sector is closely aligned to those dual aims and every time a new generic or biosimilar molecule is listed on the Pharmaceutical Benefits Scheme, it triggers the release of millions of dollars in savings to the Government and relief to patients," said GBMA chair Professor Jane Halton AO PSM. …